Using their Trimera mouse system to produce human antibodies to the hepatitis C virus, XTL Biopharmaceuticals claims
that these antibodies are more potent and specific and more effective than previously generated antibodies. (The Trimera
mouse has been genetically altered to carry human tissues for in vivo [in a living organism] experiments.) These antibodies
are now being investigated, and the product is called Nabi-Civacir. Tested in chimpanzees with encouraging results, Nabi-Civacir,
(a.k.a. H-CIG) is a human antibody to hepatitis C, derived from screened donors. These antibodies neutralize the hepatitis C virus
and it is hoped they might prevent HCV infection or subsequent re-infection. The product is now in Phase II trials in transplant patients.
In several animal studies, sustained levels of Civacir seemed to reduce viral loads, and possibly eliminate HCV altogether. More studies are required (
).
XTL has another product, HCV-AB68, a monoclonal antibody. Phase 1A trials involving one application in a
few Hep C patients have been completed, showing it to be safe, well-tolerated and effective. Dose-escalating trials are underway
(
